Northwest Biotherapeutics, Inc. (NWBO)

0,4511 -0,0019 (-0,42%) Börsenschluss: 03:56PM EDT

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 25

Beschreibung

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate Governance

Northwest Biotherapeutics, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.